PhRMA’s Medicare Demos Would Pair Voluntary Price Discounts With Reduced Cost Sharing

Whether an opening gambit for negotiation or the most industry is willing to concede, proposals being offered by industry to replace the Trump Administration’s plan to pursue international reference pricing for Part B drugs seem modest.

WASHINGTON, DC - JUNE 12, 2019: President Donald Trump pauses with a serious face during a press conference in the Rose Garden of the White House with Polish President Andrzej Duda.
PhRMA In Discussions With White House On Drug Pricing

The Pharmaceutical Research and Manufacturers of America is floating proposals to lower prescription drug costs in Medicare Part B and Part D through voluntary demonstration projects in which manufacturer discounts would help lower beneficiary cost sharing.

The proposals could serve as an alternative to the so-called “most favored nation” executive order the President has threatened to...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet